Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells

Hiba Ahmad Zahreddine and Katherine L.B. Borden

Abstract

Drug resistance remains a major impediment in the development of durable cancer therapies. Studies in acute myelogenous leukemia (AML) patients revealed a new form of multidrug resistance. Here, increased glioma-associated protein GLI1 leads to elevation of the UDP-glucuronosyl transferase (UGT) enzymes. UGTS add glucuronic acid to xenobiotics and metabolites. Traditionally, the loss of these enzymes is thought to contribute to cancer as a result of impaired clearance of environmental carcinogens. However, we demonstrate that overexpression of UGTs may contribute to oncogenesis by promoting drug resistance. Indeed, UGT levels in AML patients treated with ribavirin and/or cytarabine were elevated at relapse relative to diagnosis. This was reversed by GLI1 inhibition, suggesting a clinically relevant strategy to overcome drug resistance. Further, overexpression of UGTs can also lead to drug resistance in other cancers, such as certain Hsp90 inhibitors and vorinostat in colorectal and chronic lymphoblastic leukemia, respectively. Not all drugs are targets of glucuronidation, suggesting that UGT status could be relevant to treatment choice. Here, we describe several facets of UGT biology and how these could be exploited clinically. These studies demonstrate how drugs in cancer cells can be metabolized differentially than their normal counterparts. In summary, we describe a new form of drug resistance relevant to a variety of cancer contexts. Clin Cancer Res; 21(10); 2207–10. © 2015 AACR.

Background

The development of durable cancer therapeutics continues to be impaired by the development of drug resistance, which arises to both traditional chemotherapies and newly developed targeted treatments. Drug resistance can arise for many different reasons, including modulation of drug transporters and/or metabolism, mutation of protein targets of drugs, and rewiring of targeted pathways, to name a few (1, 2). Further complicating matters, the development of resistance to one drug can lead to resistance to drugs that the patient has never received. This is referred to as cross-resistance (1). For instance, increased drug efflux through the MDR transporters affects many drugs. Genetic rewiring can lead to oncogenic bypass, where the drug still hits its cellular target, but no longer has a physiologic effect (2). Below, a new form of multidrug resistance is described, inducible drug glucuronidation (Fig. 1), which was discovered while targeting the eukaryotic translation initiation factor 4E (eIF4E) with a small-molecule inhibitor ribavirin in acute myelogenous leukemia (AML) patients (3). Initially, these results were quite promising, with some refractory and relapsed patients achieving complete and partial remissions with ribavirin monotherapy and also ribavirin in combination with low-dose Ara-C (4, 5). However, all patients eventually relapsed, and investigations into the molecular reasons for this led to the discovery that ribavirin and Ara-C became glucuronidated specifically in resistant cells.

Glucuronidation is an important step in phase II drug metabolism (6). There are several glucuronidation enzymes, UDP-glucuronosyl transferases, which are divided into two major families: UGT1As with nine members and UGT2B with seven members (7). UGT1As catalyze the addition of glucuronic acid to the nucleophilic part of the drug, rendering it more hydrophilic and either enhancing its efflux or modulating its affinity for a given cellular target. Family members differ in their preference to target specific chemical moieties, such as nitrogens, sulphurs, and oxygen (8). This activity, once thought limited to the liver, can occur throughout the body (8). Although glucuronidation is usually considered a steady-state process, it can have somewhat unpredictable effects. For instance, glucuronidation of morphine increases its potency (6), while glucuronidation of testosterone modulates its repertoire of protein partners without altering efflux (6).

Analysis of model systems and material from AML patients who had received either ribavirin or standard-of-care therapies revealed that levels of the sonic hedgehog transcription factor GLI1 became substantially elevated upon drug resistance, and this correlated with an increase in levels of the UGT1As enzymes (3, 5). Here, it was shown that this family of enzymes mediated glucuronidation of ribavirin, resulting in the loss of the ribavirin–eIF4E interaction and ultimately the loss of response to the drug. It was noted that, in this case, glucuronidation did not modulate the efflux of ribavirin. Furthermore, inducible glucuronidation was also observed for cytarabine, the cornerstone in the treatment for AML. Preliminary studies suggest other drugs will also be targets for this mode of inactivation (H.A. Zahreddine and K.L.B. Borden; unpublished results). Excitingly, this mechanism is reversed by the genetic or pharmacologic inhibition of GLI1, including with vismodegib.

Institute of Research in Immunology and Cancer (IRIC), Department of Pathology and Cell Biology, Université de Montréal, Montreal, Quebec, Canada.

Corresponding Author: Katherine L.B. Borden, Institute of Research in Immunology and Cancer (IRIC), Université de Montréal, Pavillon Marcelle-Coutu, 2950, Chemin Polytechnique, Montreal, QC H3T 1J4, Canada. Phone: 514-343-6291; Fax: 514-343-5839; E-mail: katherine.borden@umontreal.ca
doi: 10.1158/1078-0432.CCR-14-1370
©2015 American Association for Cancer Research.

www.aacrjournals.org
a drug approved for metastatic basal cell carcinoma. Thus, our studies reveal a potential strategy to overcome drug resistance, which will be tested in AML patients in the coming months (NCT02073838).

**Clinical–Translational Advances**

**Relevance of UGTs to drug resistance**

Most studies on glucuronidation in malignancy have focused on the effects of loss of UGTs. Such losses can lead to reduced clearance of xenobiotics, such as the carcinogens in cigarette smoke (9). In the absence of clearance of these metabolites, increased DNA damage can occur leading to cancer (9). In support of this idea, individuals that lack activity of UGT1A7 have a higher risk of lung cancer (9).

Recent studies demonstrate that glucuronidation can become elevated in malignancy (3, 5, 10, 11). This result suggests that there is some sort of “Goldilocks zone” for UGT expression, where levels should not be too high or too low, but rather “just right.” Our studies show that inducible drug glucuronidation can be part of an adaptive response of cancer cells to evade the effects of certain drugs. Furthermore, these new findings demonstrate that cancer cells metabolize drugs differently than normal counterparts. For instance, ribavirin- and cytarabine-glucuronides are not observed in normal tissues. Indeed, this metabolism even differs amongst cancer cell populations (resistant versus responsive). Two other recent studies support this hypothesis and suggest that these findings go beyond AML.

First, in chronic lymphocytic leukemia (CLL), elevation of UGT2B17 may also underpin drug resistance (10). In these studies, elevated UGT2B17 mRNA expression, in conjunction with other prognostic markers for CLL, predicted significantly shorter survival. Indeed, glucuronides are observed for the HDAC inhibitor vorinostat upon UGT2B17 overexpression; suggesting that UGT2B17 may have an impact on drug response at least in some patients. In a separate study, resistance to some Hsp90 inhibitors in a subset of colorectal cancer cell lines directly correlated with increased expression and enzymatic activity of UGT1As (11). Glucuronidation abrogated the Hsp90 interaction of a subset of chemically related inhibitors (11). Chemically unrelated Hsp90 inhibitors were not modified and still targeted Hsp90 in these cells, demonstrating the specificity of targeting in these cells. For the glucuronidation target drugs, knockdown of UGT led to renewed drug sensitivity. Given that not all Hsp90 inhibitors were targets for glucuronidation, specific UGTs likely play a role with these, favoring specific chemical moieties for glucuronidation. In summary, evidence for inducible drug glucuronidation is observed in several contexts, including AML, CLL, and colorectal cancers.

**Regulation and targeting of UGTs**

In order to develop means to target UGTs, it is critical to understand how these enzymes are regulated (Fig. 1). UGT levels can be regulated both posttranscriptionally and transcriptionally. For the AML case, there is a clear correlation.
between elevated GLI1 and UGT protein levels. Further, reduction of GLI1 by knockdown or pharmacologic targeting with vismodegib or GANT61 leads to reduced UGT levels and reverses drug resistance. However, UGT is not a transcriptional target of GLI1, as UGT1A mRNA levels are not elevated. However, GLI1 appears to increase UGT1A protein stability. We postulate that GLI1 decreases UGT1A protein turnover through downregulation of specific protein ligases or it induces some posttranslational modifications of these enzymes, rendering them less susceptible to degradation. These possibilities will be examined in the future. Hence, in addition to using GLI1 inhibitors as a means to revert resistance, identifying key factors mediating the link between GLI1 and UGT1A could also serve as potential therapeutic modalities.

It seems likely that there will be many pathways leading to UGT dysregulation upon cancer resistance, in addition to GLI1 dysregulation. Numerous recent studies revealed a variety of molecular mechanisms governing expression and activity of UGT enzymes (11–15). Due to space restraints, only a few of these are described here. Aside from effects on protein stability described above, these include transcriptional regulation, phosphorylation, DNA methylation, histone modification, microRNA regulation, as well as alternative splicing (11–15). For instance, DNA hypermethylation of the UGT1A1 promoter correlated with reduced transcription and increased sensitivity of colorectal cancer cells to SN-38 (the active metabolite of irinotecan; ref. 12). Also, a recent study identified microRNAs that negatively regulate the expression of UGT2B17 in human liver samples, but the identity of these microRNAs remains to be experimentally validated (14). Another interesting discovery revealed the presence of a novel class of human UGT proteins named UGT isoforms 2 (or i2s; ref. 16). Like isoforms 1, i2s are encoded by the same genetic locus, but instead of incorporating the usual common C-terminus exon 5a, these utilize a shorter exon 5b that causes a premature arrest of translation and subsequent loss of the transmembrane domain. Consequently, UGT i2s are located in the lumen and cytoplasm rather than in the membrane of the endoplasmic reticulum. Functionally, the i2 enzymes lack glucuronidation activity but act in a dominant-negative capacity, possibly by forming inactive heteromeric complexes with i1 enzymes, thus reducing enzymatic activity. Recent reports showed differential i1:i2 expression ratio in normal versus cancer tissues, with increased i2 in liver tumors and decreased levels of i1 and i2 in colon cancer samples, compared with normal specimens (17). Given the close tie between protein levels and activity, it seems likely that these tumors will have different glucuronidation activity relative to normal controls. As such, understanding the mechanisms of regulation of i2s might provide a means for increasing their expression in resistance context, allowing for inhibition of UGT i1s, as one of many possible targeting strategies.

Inducible modifications beyond glucuronidation?
Phases II drug metabolism involves conjugation of drugs via multiple pathways, including sulfation, glutathione addition, acetylation, methylation as well as glucuronidation. Accordingly, similar to glucuronidation, one can speculate that these modifications may also be induced in some forms of drug resistance. As such, a better understanding of the mechanisms that control these enzymes in both normal and cancer contexts could help improve the efficacy of cancer therapy. In addition, our findings suggest that when developing drugs, mechanisms that could drive drug modifications should be considered in patients particularly at relapse and not only in the initial stages of drug development in normal cells.

Conclusions and Future Directions
UGTs could not only serve as a biomarker for drug resistance but also guide choice of treatment. For instance, knowledge of which Hsp90 inhibitors become glucuronidated in cell lines would be important for guiding which inhibitors to administer when UGT levels become elevated in patients. In this way, the most effective Hsp90 inhibitors could be selected based on a patient’s UGT status. Once there is a more global understanding of the drugs that become glucuronidated in different cancer contexts, UGT status could be used more globally for guiding the best options for other treatments. In AML, we will examine the efficacy of targeting glucuronidation by combining the GLI1 inhibitor vismodegib to target glucuronidation with ribavirin to target elevated eIF4E (NCT02073838). In this way, we will examine the efficacy of targeting UGT as a means to overcome drug resistance in patients.

One of the great challenges in studying drug metabolism is developing appropriate model systems. Human cell lines have been used for such experiments but are limited in terms of monitoring in vivo disease and further recapitulating drug compartmentalization and associated features. However, the substantial differences in drug modifications and even drug transporter distribution, between humans and rodents (18–20), means that this is a difficult solution as well. For instance, rodents have no N-linked glucuronidation, which is a major pathway in humans. Mice with human UGT1As expressed in their liver have more similar, but still not identical, glucuronidation activity as humans (19). Further issues arise as there are glucuronidation enzymes that are mainly in the gastrointestinal track and thus would not be accounted for by the humanized liver model (19). Other species-specific aspects of drug metabolism need to be accounted for as well, such as differences in drug transporter distribution (20). Thus, only with great effort and care can a model system be developed to truly parallel the human system.

In summary, inducible drug glucuronidation as a novel form of multidrug resistance is described. A better understanding of the modalities that cause UGT dysregulation will likely provide therapeutic strategies beyond the GLI1 example used here. Such studies should include monitoring UGTs at the protein level in various types and stages of cancer to assess the scope of this dysregulation. Also, determining which of the UGTs is upregulated in a given type of cancer first will help predict which class(es) of drugs will be subject to glucuronidation and potentially guide treatment choice. Finally, our studies strongly suggest that drug metabolism can differ between cancer and normal cells. These differences need to be better defined and could be a launching point for novel therapeutic strategies.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: H.A. Zahreddine, K.L.B. Borden
Development of methodology: H.A. Zahreddine, K.L.B. Borden
Writing, review, and/or revision of the manuscript: H.A. Zahreddine, K.L.B. Borden

Grant Support
H.A. Zahreddine is supported by a Cole Foundation Fellowship. K.L.B. Borden is supported by grants from the NIH (ROI 80728 and 98571), the Leukemia and Lymphoma Society Translation Research Program, and the Canadian Cancer Society Research Institute and holds a Canada Research Chair.

Received November 14, 2014; revised February 10, 2015; accepted February 19, 2015; published OnlineFirst March 25, 2015.

References
16. Giraud H, Levesque E, Bellmane J, Journault K, Cailler B, Guillemette C. Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics 2007;17:1077–89.